Search results
Results from the WOW.Com Content Network
GSK did price the authorized generic lower than branded Flovent; one package of Flovent HFA in the 110 microgram dose, for example, costs $273.83, about 50% more than the $177.99 wholesale ...
The discontinuation aligns with a change to Medicaid rebates that may have had the inhaler’s manufacturer selling the drug at a loss. Popular asthma inhaler will be discontinued Jan. 1. Here’s ...
"Flovent and its generic version Fluticasone are delivered via something called a metered dose inhaler, and it's used with a spacer. These pumps are very easy to use for young children," Conrad says.
Fluticasone propionate, sold under the brand names Flovent and Flonase among others, is a glucocorticoid steroid medication. [8] When inhaled it is used for the long term management of asthma and COPD. [8] In the nose it is used for hay fever and nasal polyps. [9] [10] It can also be used for mouth ulcers. [11] It works by decreasing inflammation.
Diversion, abuse, and a relatively high rate of overdose deaths in comparison to other drugs of its group. This drug continues to be available in most of the world including the US, but under strict controls. Terfenadine (Seldane, Triludan) 1997–1998 France, South Africa, Oman, others, US Prolonged QT interval; ventricular tachycardia [2] [3]
Fluticasone Furoate falls under the drug class of Corticosteroid. Corticosteroids are a class of steroid hormones produced naturally by the adrenal cortex, which is located on top of the kidneys. They play a crucial role in regulating various physiological processes in the body, including metabolism, immune response, and inflammation.
Formulations of delayed-release budesonide are an effective treatment for mild-to-moderately active Crohn's disease involving the ileum and/or ascending colon. [25] A Cochrane review found evidence for up to three months (but not longer) of maintenance of remission in Crohn's disease, concluding that budesonide is not effective for maintenance of remission in CD.
LONDON -- "Big pharma" giant GlaxoSmithKline (NYS: GSK) slightly disappointed its owners today, as its latest results revealed low growth in turnover and earnings. GSK's slow growthAs soon as GSK ...